peptide
PT-141 (Bremelanotide)
strongFDA-Approved· RxInjection
Boosts sexual desire through melanocortin receptors in the brain, not blood vessels. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Key facts
- Classification
- PT-141 (Bremelanotide) selectively activates MC4R in the CNS to initiate sexual arousal through dopaminergic pathways.
- Primary benefits
- Mood & Anxiety (4/10) · Fertility & Hormones (3/10)
- Administration
- Injection
- Doses studied
- 1.75 mg subq about 45 minutes before you need it. Don't use more than once in 24 hours, and it's not meant for daily use. FDA-approved route is subcutaneous injection only.
- Evidence strength
- Strong — 20 peer-reviewed studies
- Stacks well with
- Kisspeptin-10
- Legal status
- FDA-Approved · prescription required
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 20
- Stacks with
- 1 peptide
- Regulatory
- FDA-Approved
Scientific overview
PT-141 (Bremelanotide) selectively activates MC4R in the CNS to initiate sexual arousal through dopaminergic pathways. FDA-approved as Vyleesi for HSDD in premenopausal women. Acts centrally rather than on peripheral vasculature.
Goal coverage · PT-141 (Bremelanotide)
😌 Mood & Anxiety4/10
🧬 Fertility & Hormones3/10
Medical oversight requiredNot safe during pregnancy· 4 contraindications